Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics.

Citation data:

BMC psychiatry, ISSN: 1471-244X, Vol: 14, Issue: 1, Page: 23

Publication Year:
2014
Usage 544
Abstract Views 356
Full Text Views 101
Downloads 84
Link-outs 3
Captures 34
Readers 25
Exports-Saves 9
Mentions 1
Blog Mentions 1
Citations 17
Citation Indexes 17
Repository URL:
https://ro.uow.edu.au/smhpapers/1496
PMID:
24472577
DOI:
10.1186/1471-244x-14-23
PMCID:
PMC3907147; 3907147
Author(s):
Newell, Kelly A; Matosin, Natalie
Publisher(s):
Springer Nature
Tags:
Medicine; Metabotropic glutamate receptor; mGlu; mGluR5; GRM; Schizophrenia; Depression; Post-mortem human brain; Novel antipsychotic; Novel antidepressant; Glutamate; CMMB; Medicine and Health Sciences; Social and Behavioral Sciences
Most Recent Blog Mention
article description
Pharmacological modulation of metabotropic glutamate receptor 5 (mGluR5) is of marked interest as a novel therapeutic mechanism to treat schizophrenia and major depression. However, the status of mGluR5 in the pathophysiology of these disorders remains unknown.